Bristol Myers Squibb stock holds near analyst price target as earnings outlook firms
Published on 09/14/2026 at 14:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock (ISIN US0897961004) opened at USD 63.52 on the New York Stock Exchange on September 14, 2026, only modestly below the analyst consensus price target of USD 66.33 for the shares, according to an overview from MarketBeat on September 14, 2026.
Analysts lift EPS estimates while guidance stays intact
According to MarketBeat on September 14, 2026, Zacks Research raised its forecast for Bristol Myers Squibb's fiscal 2026 earnings per share to USD 6.86, nudging it up from a previous estimate of USD 6.85.
The same research summary notes that the consensus estimate for the company’s current full-year earnings stands slightly higher at USD 6.95 per share, while Bristol Myers Squibb itself has set guidance for fiscal 2026 EPS in a range of USD 6.75 to USD 7.00, indicating that the consensus now sits close to the upper half of management’s own outlook, as reported by MarketBeat.
Stock trades near consensus target
In the same snapshot, MarketBeat reports that Bristol Myers Squibb shares opened at USD 63.52 on the New York Stock Exchange on September 14, 2026, putting the stock approximately USD 2.81, or about 4.4 percent, below the consensus analyst price target of USD 66.33.
The same overview states that analysts as tracked by MarketBeat currently assign Bristol Myers Squibb a consensus rating of Moderate Buy, underlining that a majority of covering houses still see upside in the shares relative to the present trading level.
Closing price context and recent performance
An earlier price snapshot shows that Bristol Myers Squibb stock closed at USD 63.52 on the New York Stock Exchange on September 11, 2026, marking a daily decline of 0.35 percent, according to a brief market update citing MarketBeat data on September 14, 2026.
Another recent analysis of the shares highlights that Bristol Myers Squibb stock has gained nearly 35 percent since September 2025, pointing to a strong recovery over the past year from lower levels, as discussed in a performance-focused review on September 13, 2026 that cited a current trading level of USD 63.64 within an intraday range between USD 63.27 and USD 64.20.
Stock price and valuation snapshot
Based on the opening price of USD 63.52 on the New York Stock Exchange on September 14, 2026, and using the consensus current-year EPS estimate of USD 6.95 from MarketBeat, Bristol Myers Squibb is trading at roughly 9.1 times expected earnings, a valuation level that places the shares below many high-growth biotechnology peers but broadly in line with other large-cap pharmaceutical names.
Bristol Myers Squibb stock key data
- Company: Bristol Myers Squibb Company
- ISIN: US0897961004
- Ticker: BMY
- Trading venue: New York Stock Exchange
- Price (as of September 14, 2026): 63.52 USD
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
